Tranzyme Pharma is a clinical-stage biopharmaceutical company developing novel small molecule drugs for both acute (hospital-based) and chronic disorders with high unmet medical needs. The Company's pipeline, derived from its proprietary MATCH™ technology, targets two validated GPCR drug targets, ghrelin and motilin. Tranzyme's lead products, TZP-101 (for postoperative ileus and acute gastric motility disorders) and TZP-102 (for gastroparesis) are potent ghrelin agonists entering Phase 3 and Phase 2 clinical trials, respectively, in Q109. TZP-301, a ghrelin antagonist for the treatment of obesity and metabolic syndrome, and TZP-201, a motilin antagonist for the treatment of moderate-to-severe diarrhea, are advancing in development.

Upcoming Events

Bio International 2009

May 18-21, 2009
Georgia World Congress Ctr
Atlanta, GA
Digestive Disease Week

May 30 - Jun 4, 2009
McCormick Place
Chicago, IL
American Diabetes Association

Jun 5-9, 2009
Morial Convention Center
New Orleans, LA

» More Events

Download a Company Fact Sheet